Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
86°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
114.54
+1.30 (+1.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
December 20, 2024
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Via
Investor's Business Daily
COVID-19 is Not the Same Disease for Everyone
December 20, 2024
(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated...
Via
Brandpoint
Topics
Death
(GILD) - Analyzing Gilead Sciences's Short Interest
December 19, 2024
Via
Benzinga
Is GILEAD SCIENCES INC Ready to Break Out of Its Range?
December 19, 2024
In-Depth Technical Analysis of GILEAD SCIENCES INC.
Via
Chartmill
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
December 16, 2024
Via
Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
December 13, 2024
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
Via
Benzinga
What Analysts Are Saying About Gilead Sciences Stock
December 10, 2024
Via
Benzinga
Looking At Gilead Sciences's Recent Unusual Options Activity
December 03, 2024
Via
Benzinga
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
December 12, 2024
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.
Via
Benzinga
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
December 09, 2024
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
December 09, 2024
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.
Via
Benzinga
Price Over Earnings Overview: Gilead Sciences
November 25, 2024
Via
Benzinga
26 Analysts Assess Gilead Sciences: What You Need To Know
November 18, 2024
Via
Benzinga
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
November 15, 2024
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety.
Via
Benzinga
3 Healthcare Stocks For Long-Term Growth And Dividends
November 07, 2024
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time.
Via
Talk Markets
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
November 06, 2024
Via
Benzinga
Gilead Sciences's Earnings: A Preview
November 05, 2024
Via
Benzinga
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low
November 15, 2024
The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows.
Via
Benzinga
Topics
Government
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 10, 2024
High yields aren't a warning indicator with these three stocks.
Via
The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...
Via
Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
November 08, 2024
A Fed rate cut and a slew of big earnings reports filled out a busy week.
Via
Investor's Business Daily
Topics
Economy
Government
Smaller Cap Biotechs Are In Season: How Are We Doing?
November 07, 2024
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Via
Talk Markets
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
November 07, 2024
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence.
Via
Benzinga
Topics
Earnings
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
November 07, 2024
After Wednesday’s “everything rally” spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting. The Fed is widely...
Via
Benzinga
Topics
Economy
Gilead’s Stock Surge: What’s Fueling the Momentum?
November 07, 2024
Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth.
Via
MarketBeat
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
November 06, 2024
GILD earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales
November 06, 2024
The company also raised its earnings and sales guidance for the year.
Via
Investor's Business Daily
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
November 04, 2024
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.
Via
Talk Markets
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
October 30, 2024
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.
Via
Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
These stocks are trading at less than 15 times their expected future profits.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.